摘要
目的:比较单药吉西他滨与吉西他滨联合奥沙利铂治疗非小细胞肺癌的疗效。方法:将75例非小细胞肺癌随机分为两组,21例单纯应用吉西他滨化疗(单药组),54例采用吉西他滨联合奥沙利铂化疗(联合组),对其疗效及毒副反应进行观察。结果:单药组和联合组有效率分别为23.8%和40.7%(χ2=1.881,P>0.05),WBC减少总的发生率57.1%和55.6%(χ2=0.015,P>0.05),PLT减少总的发生率52.4%和35.2%(χ2=1.863,P>0.05)。结论:单药吉西他滨与吉西他滨联合奥沙利铂治疗非小细胞肺癌安全有效,后者在临床有效率方面优于前者,但是该差异无显著性。
Objective To compare the clinical efficacy of Gemcitabine alone with Gemcitabine plus Oxaliplatin in treatment of non small-cell lung cancer.Methods Seventy-f ive patients were randomly assigned to receiving either gemcitabine alone(control group) or gemcitabine plus Oxaliplatin(combined group).The therapeutic eff icacy and toxic side effects were evaluated.Results CR+PR were 23.8% in control group and 40.7% in combined group(χ2=1.881,P>0.05).The rate of leucopenia were 57.1% and 55.6% respectively(χ2=0.015,P>0.05).The rate of thrombocytopenia were 52.4% and 35.2%(χ2=1.863,P>0.05).Conclusion Both of the two methods were effective and safe enough for non small-cell lung cancer.Gemcitabine plus Oxaliplatin might be better than gemcitabine alone in clinic.Though it did not attain statistical signif icance.
出处
《临床医药实践》
2008年第14期550-551,共2页
Proceeding of Clinical Medicine
